NCAM1 and COVID-19: In COVID-19, previous reports have showed that there was a reduced percentage of CD3+CD56+ NKT like cells in the peripheral blood of severe group compared to those of mild group, and circulating NKT-like cell frequency could be identified as a predictive biomarker for clinical outcome 14, 15.